Curis (CRIS) Stock Forecast & Price Target

Curis is viewed favorably because its emavusertib-based dual blockade strategy directly addresses a key weakness in BTKi monotherapy in CLL—high response rates but low depth, such as a 93% ORR versus only 7% CR in the zanubrutinib registrational study—and the company has already reported deeper responses, including CRs and undetectable MRD, when emavusertib is added to a BTKi regimen in NHL. The investment case is further strengthened by increasingly compelling PCNSL data, where as of July 1, 2026 emavusertib plus ibrutinib showed a 100% ORR in five of five evaluable BTKi-naïve patients and 86% in seven of seven all-patient reads, while BTKi-experienced patients still generated a meaningful 33% ORR in evaluable patients and 26% across all 39 patients, supporting regulatory discussions for accelerated approval in the U.S. and Conditional Marketing Authorization in Europe. Curis also has strategic optionality from management’s intent to expand emavusertib across all five NHL subtypes, and the TakeAim CLL design—enrolling patients already in partial response on zanubrutinib for at least 12 months and MRD-positive by clonoSEQ—creates a cleaner read on incremental efficacy that could validate the platform beyond a single indication.

Curis is facing a fundamentally fragile investment case because its most important registrational dataset in relapsed/refractory primary CNS lymphoma (PCNSL) shows only a 26% objective response rate (10 of 39) on an all-patients basis as of July 1, 2026, essentially unchanged from 27% (7 of 26) despite the cohort expanding by 50%, while 23% of patients failed to complete even one 28-day cycle, raising concerns that the headline efficacy may be inflated by excluding the sickest or least tolerant patients. The reliance on an accelerated-approval path makes this even more precarious, since the full enrolled population is likely to matter most to regulators and the evaluable set would only be a supportive sensitivity analysis, meaning the current data may not withstand a stricter FDA review if the low response rate and discontinuations are weighted more heavily. Its chronic lymphocytic leukemia program also appears weak as a value driver, with the thesis carrying only a 10% probability of success despite the biological rationale, and although the company raised year-end guidance for TakeAim CLL, the underlying need to show durable incremental benefit beyond zanubrutinib remains unproven and leaves the stock dependent on a risky December readout.